Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd., an Australian pharmaceutical company, has released its 2024 Corporate Governance Statement, outlining the strategic roles and responsibilities of its board and management. The statement highlights the company’s commitment to enhancing long-term shareholder value through stringent oversight and accountability systems. Amplia is focused on advancing a pipeline of FAK inhibitors, targeting cancer and fibrosis, with a special emphasis on fibrotic cancers like pancreatic and ovarian cancer.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
